Pro- and anti-fibrotic agents in liver fibrosis: Perspective from an ex vivo model of liver fibrosis

Suriguga, S., 2019, 186 p.

Research output: ThesisThesis fully internal (DIV)

Copy link to clipboard


  • Title and contents

    Final publisher's version, 288 KB, PDF document

  • Chapter 1

    Final publisher's version, 7.66 MB, PDF document

  • Chapter 2

    Final publisher's version, 12.6 MB, PDF document

  • Chapter 3

    Final publisher's version, 58.4 MB, PDF document

  • Chapter 4

    Final publisher's version, 2.88 MB, PDF document

  • Chapter 5

    Final publisher's version, 3.49 MB, PDF document

  • Chapter 6

    Final publisher's version, 3.16 MB, PDF document

  • Chapter 7

    Final publisher's version, 1.48 MB, PDF document

  • Chapter 8

    Final publisher's version, 173 KB, PDF document

  • Appendix

    Final publisher's version, 1.37 MB, PDF document

  • Complete thesis

    Final publisher's version, 75.8 MB, PDF document

  • Propositions

    Final publisher's version, 29.9 KB, PDF document

  • S. Suriguga
This thesis provides new insight into the association of the gut-liver axis with liver fibrosis and demonstrates that the development of small molecule inhibitors of the TGF-β signaling pathway is an encouraging strategy to extenuate liver fibrosis. In addition, modulating oxidative stress, another pro-fibrogenic signal, might provide a bright future for combatting liver fibrosis. Moreover, we exhibited here a promising ex-vivo tool, the precision-cut liver slices, for its application in exploring mechanism of liver fibrosis as well as in anti-fibrotic drug discovery in a clinically relevant situation, thereby reducing and refining animal experiments.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
Award date8-Apr-2019
Print ISBNs978-94-034-1551-2
Electronic ISBNs978-94-034-1550-5
Publication statusPublished - 2019

Download statistics

No data available

ID: 78704477